Leslie J. Browne
Vorsitzender bei Phrixus Pharmaceuticals, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Thomas A. Collet | M | - |
Phrixus Pharmaceuticals, Inc.
 Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | 18 Jahre |
| Bruce Edward Markham | M | - |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | 18 Jahre |
| Dennis G. Severance | M | 80 |
University of Michigan
| 46 Jahre |
| Bertram Pitt | M | 92 |
University of Michigan
| 47 Jahre |
| Gerald D. Brennan | M | 73 |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | - |
| James Symons | M | - |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | - |
| Joseph Metzger | M | - |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mitch A. Mondry | M | - |
University of Michigan
| 8 Jahre |
| Fred Driscoll | M | 73 |
Genelabs Technologies, Inc.
 Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | 2 Jahre |
| Ronald Martell | M | 62 |
Sevion Therapeutics, Inc.
 Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | 1 Jahre |
| Jack van Hulst | M | 85 |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | 7 Jahre |
| Vaughn V. Smider | M | 54 |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | - |
| Phillip Frost | M | 87 |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | - |
| James MacFarlane Cook | M | - |
University of Strathclyde
| 7 Jahre |
| Elliot Noma | M | - |
University of Michigan
| 4 Jahre |
| Mary L. Campbell | F | - |
University of Michigan
| 2 Jahre |
| Roy Liu | M | 63 |
University of Michigan
| 10 Jahre |
| James Neal | M | 68 |
Iconix Biosciences, Inc.
 Iconix Biosciences, Inc. BiotechnologyHealth Technology Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix. | 5 Jahre |
| David E. Goldberg | M | - |
University of Michigan
| 5 Jahre |
| John Sloss | M | - |
University of Michigan
| 7 Jahre |
| Charan Behl | M | 72 |
University of Michigan
| 5 Jahre |
| Mike Sayama | M | 69 |
University of Michigan
| 4 Jahre |
| Thomas J. Fleszar | M | - |
University of Michigan
| 11 Jahre |
| Rene Belder | M | 66 |
Pharmacopeia LLC
 Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | - |
| Roy Anderson | M | 76 |
Genelabs Technologies, Inc.
Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | - |
| James R. Downing | M | 69 |
University of Michigan
| 8 Jahre |
| Peter Menard | M | 70 |
University of Michigan
| 4 Jahre |
| Norrie Stanley | M | - |
University of Strathclyde
| 6 Jahre |
| Kevin B. Hoppe | M | - |
University of Michigan
| 6 Jahre |
| George H. Vincent | M | - |
University of Michigan
| 7 Jahre |
| Richard J. Scheidt | M | 70 |
University of Michigan
| 6 Jahre |
| Rick M. Albert | M | - |
University of Michigan
| 7 Jahre |
| Anmar Karim Sarafa | M | - |
University of Michigan
| 4 Jahre |
| Dave Spaight | M | - |
University of Michigan
| 12 Jahre |
| Gabriel Shaheen | M | 70 |
University of Michigan
| 5 Jahre |
| Paul F. DePond | M | 69 |
University of Michigan
| 5 Jahre |
| David Russell Borger | M | - |
University of Michigan
| 3 Jahre |
| Richard S. Dondero | M | 74 |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | 10 Jahre |
| Warren John Isabelle | M | 71 |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | 5 Jahre |
| Charles Schrock | M | 69 |
University of Michigan
| 6 Jahre |
| Steven Rubin | M | 63 |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | - |
| Stephen C. Costalas | M | 51 |
Pharmacopeia LLC
Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | - |
| John E. Thompson | M | 82 |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | 15 Jahre |
| Rudolf Stalder | M | 83 |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | 15 Jahre |
| Thomas C. Quick | M | 68 |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | 15 Jahre |
| Manggi Taruna Habir | M | 71 |
University of Michigan
| 2 Jahre |
| David B. Papworth | M | 68 |
University of Michigan
| 4 Jahre |
| Charles K. Nicholas | M | - |
University of Michigan
| 4 Jahre |
| Tim Hurley | M | - |
University of Michigan
| 4 Jahre |
| Dilip K. Nigam | M | - |
University of Michigan
| 4 Jahre |
| Donald W. Moran | M | - |
University of Michigan
| 4 Jahre |
| John R. Gerstein | M | - |
University of Michigan
| 3 Jahre |
| Lawrence A. Schneider | M | - |
University of Michigan
| 4 Jahre |
| Michael Joseph Stark | M | 68 |
University of Michigan
| 2 Jahre |
| Patrick L. Beach | M | - |
University of Michigan
| 4 Jahre |
| Chris Bugg | M | - |
University of Michigan
| 4 Jahre |
| Min-Koo Han | M | 75 |
University of Michigan
| 1 Jahre |
| Steve R. Hibshman | M | - |
University of Michigan
| 4 Jahre |
| Joseph Keithley | M | 75 |
University of Michigan
| 2 Jahre |
| Edward B. Matthew | M | 68 |
University of Michigan
| 4 Jahre |
| John B. Palmer | M | - |
University of Michigan
| 3 Jahre |
| Henry Yu | M | 70 |
University of Michigan
| 4 Jahre |
| Robert N. Garff | M | 72 |
University of Michigan
| 2 Jahre |
| Jeff Mackevich | M | - |
University of Michigan
| 4 Jahre |
| Peter Michael Swift | M | 79 |
University of Michigan
| 5 Jahre |
| Americo Nesti | M | 70 |
University of Michigan
| 4 Jahre |
| Michael McCabe | M | 67 |
University of Michigan
| 4 Jahre |
| Michael Pepke | M | - |
University of Michigan
| 1 Jahre |
| Chris Williams | M | - |
University of Michigan
| 4 Jahre |
| Daniel R. Williamson | M | - |
University of Michigan
| 4 Jahre |
| Arthur A. Tomaro | M | - |
University of Michigan
| 4 Jahre |
| Gregory Gallopoulos | M | 65 |
University of Michigan
| 4 Jahre |
| Thomas J. Shea | M | - |
University of Michigan
| 4 Jahre |
| Kevin Longe | M | 65 |
University of Michigan
| 4 Jahre |
| Jeffrey B. Yapp | M | 65 |
University of Michigan
| 4 Jahre |
| Steven M. Fetter | M | 72 |
University of Michigan
| 3 Jahre |
| Tal Gunn | M | - |
University of Michigan
| 4 Jahre |
| Hank Barry | M | - |
University of Michigan
| 4 Jahre |
| Gregory P. Hanson | M | 77 |
University of Michigan
| 2 Jahre |
| Mark Carl Lahti | M | - |
University of Michigan
| 4 Jahre |
| Syed Hyder Ali | M | - |
University of Michigan
| 4 Jahre |
| Ronald J. Fenech | M | 66 |
University of Michigan
| 4 Jahre |
| Rosy Rosenberg | M | 71 |
University of Michigan
| 4 Jahre |
| Andrew J. Lansing | M | - |
University of Michigan
| 4 Jahre |
| Daryl J. Carter | M | 69 |
University of Michigan
| 4 Jahre |
| Steven Klinsky | M | 67 |
University of Michigan
| 4 Jahre |
| Scott Canute | M | 63 |
University of Michigan
| 4 Jahre |
| William H. Rice | M | 67 |
University of Michigan
| 4 Jahre |
| Bruce Tanner | M | 65 |
University of Michigan
| 4 Jahre |
| George A. Lehner | M | - |
University of Michigan
| 3 Jahre |
| David C. Bahls | M | - |
University of Michigan
| 4 Jahre |
| Brian Joseph Smith | M | 72 |
University of Michigan
| 3 Jahre |
| Timothy J. Abeska | M | - |
University of Michigan
| 4 Jahre |
| David M. Floyd | M | 78 |
Pharmacopeia LLC
Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | 3 Jahre |
| Chris Theodore | M | - |
University of Michigan
| 1 Jahre |
| Laurie E. Romanak | F | 64 |
University of Michigan
| 4 Jahre |
| David Kuehl | M | - |
University of Michigan
| 3 Jahre |
| Kenneth S. Duckworth | M | - |
University of Michigan
| 4 Jahre |
| Don Huber | M | - |
University of Michigan
| 4 Jahre |
| Peter Hoag | M | - |
University of Michigan
| 3 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 98 | 98,00% |
| Vereinigtes Königreich | 2 | 2,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Leslie J. Browne
- Persönliches Netzwerk
